Advanced glycation end products (AGEs), known to accumulate during aging and at accelerated rate during the course of diabetes, have been demonstrated to induce changes in endothelial properties that might contribute to the pathogenesis of micro- and macroangiopathy. Since AGE-formation not only changes the physicochemical properties of proteins, but also induces cellular signalling, activation of transcription factors and subsequent gene expression, AGEs are now regarded as important mediators of diabetic vascular disease. The growing knowledge on the molecular mechanisms underlying the AGE-dependent activation of vascular endothelial cells implicates possible new therapeutic interventions in the therapy of diabetic angiopathy.

Maillard LC: Action des acides aminés sur les sucres: Formation des melanoïdes par voie methodique. C R Acad Sci 1912;154:66.
Njorge FG, Monnier VM: The chemistry of the maillard reaction under physiological conditions: A review. Prog Clin Biol Res 1989;304:85–107.
Thorpe S, Baynes J: Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging 1996;9:69–77.
Vlassara H, Bucala R, Striker L: Pathogenic effects of advanced glycosylation: Biochemical, biological and clinical implications for diabetes and aging. J Lab Invest 1994;70:138–151.
Bucala R, Cerami A: Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992;23:1–34.
Bucala R, Vlassara H: Advanced glycation endproducts in diabetic renal and vascular disease. Am J Kid Dis 1995;26:875–888.
Fu M-X, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW: Glycation, glycoxydation, and cross-linking of collagen by glucose: Kinetics, mechanisms and inhibition of late stages of the Maillard reaction. Diabetes 1994;43:676–683.
Dyer D, Blackledge J, Thorpe S, Baynes J: Formation of pentosidine during nonenzymatic browning of proteins by glucose: Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991;266:11654–11660.
Westwood ME, McLellan AC, Thornalley PJ: Receptor mediated endocytic uptake of methylglyoxal-modified serum albumin. J Biol Chem 1994;269:32293–32298.
Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G: The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague Dawley rat. Diabetologica 1995;38:387–394.
Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW: Mechanisms of autoxidative glycosylation: Identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 1995;34:3702–3709.
Jiang ZY, Woolard ACS, Wolff SP: Hydrogen peroxide production during experimental protein glycation. FEBS Lett 1990;268:69–71.
Hunt JV, Smith CCT, Wolff SP: Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modifications. Diabetes 1990;39:1420–1424.
Bucala R, Makita Z, Vega G: Modification of LDL by advanced glycosylation endproducts contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994;91:9441–9445.
Bucala R, Makita Z, Vega G, Cerami A, Vlassara H: Modification of LDL by advanced glycosylation endproducts contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994;91:9441–9445.
Vlassara H: Advanced glycation end-products and atherosclerosis. Ann Med 1996;28:419–426.
Takata K, Horiuchi S, Araki M, Shiga M, Saitoh M, Morino Y: Endocytic uptake of nonenzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins. J Biol Chem 1988;263:14819–14825.
Vlassara H, Brownlee M, Cerami A: High affinity receptor mediated uptake and degradation of glucose modified proteins: A potential mechanism for the removal of senscent macromolecules. Proc Natl Acad Sci USA 1985;82:5588–5592.
Yang Z, Makita Z, Horii Y, Brunelle S, Cerami A, Sehajpal P, Suthanthiran M, Vlassara H: Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: Relationship to macrophage receptor for glucose-modified proteins. J Exp Med 1991;174:515–524.
Li YM, Wojciehowicz D, Gilmore P, Shimizu N, Li J, Stitt AW, He C, Vlassara H: Molecular identity and tissue distribution of advanced glycation endproduct receptors: Relationship of p60 to OST-48 and 80KH membrane proteins. Proc Natl Acad Sci USA 1996;93:11047–11052.
Araki N, Higashi T, Mori T, Shibayama R, Kawabe Y, Kodama T, Takahasi K, Shichiri M, Hiriuchi S: Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur J Biochem 1995;230:408–415.
Vlassara H, Li Y-M, Imani F, Wojciechowicz D, Yang Z, Liu F-T, Cerami A: Identification of galectin-3 as a high affinity binding protein for advanced glycation end products (AGEs): A new member of the AGE-receptor complex. Mol Med 1996;1:634–646.
Schmidt AM, Mora R, Cao R, Yan SD, Brett J, Ramakrishnan R, Tsang TC, Simionescu M, Stern D: The endothelial cell binding site for advanced glycation end products consists of a complex: An integral membrane protein and a lactoferrin-like polypeptide. J Biol Chem 1994;269:9882–9888.
Schmidt A-M, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M, Wang F, Pan Y-C, Tsang T, Stern D: Isolation and characterisation of binding proteins for advanced glycation end products from lung tissue which are present on the endothelial surface. J Biol Chem 1992;267:14987–14997.
Esposito C, Gerlach H, Brett J, Stern D, Vlassara H: Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1989;170:1387–1407.
Li Y-M, Tan A-X, Vlassara H: Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nature Med 1995;1:1057–1061.
Schmidt AM, Yan SD, Stern DM: The dark side of glucose. Nature Med 1995;1:1002–1004.
Vlassara H: Pathogenesis of diabetic nephropathy, advanced glycation and new therapy. Med Klin 1997;92(suppl 1):29–34.
Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D: Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994;14:1521–1528.
Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, Nowygrod R, Neeper M, Przysiecki C, Shaw A, Migheli A, Stern D: Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993;143:1699–1712.
Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, Wahl P, Ziegler R, Müller M, Nawroth PP: Advanced glycation endproducts (AGEs) mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 1997;96:2262–2271.
Ritthaler U, Deng Y, Zhang Y, Greten J, Abel M, Sido B, Allenberg J, Otto G, Roth H, Bierhaus A, Ziegler R, Schmidt AM, Waldherr R, Wahl P, Stern DM, Nawroth PP: Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol 1995;146:688–694.
Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994;269:9889–9897.
Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern DM: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J Clin Invest 1995;96:1395–1403.
Wautier JL, Wautier MP, Schmidt AM, Anderson GM, Hori O, Zoukourian C, Capron L, Chappey O, Yan SD, Brett J, Guillausseau P-J, Stern DM: Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: A link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA 1994;91:7742–7746.
Bierhaus A, Chevion S, Chevion M, Quehenberger P, Hofmann M, Illmer T, Luther T, Berentshtein E, Tritschler H, Müller M, Wahl P, Ziegler R, Nawroth PP: Advanced glycation endproducts (AGEs) induced activation of NF-κB is suppressed by α-lipoic acid in cultured endothelial cells. Diabetes 1997;46:1481–1490.
Quehenberger P, Greten J, v-Riedesel J, Ziegler R, Wahl P, Speiser W, Bierhaus A, Nawroth PP: Endothelin-1 is under the control of the transcription factors p50/p65 (NF-κB) and AP-1 (abstract). Ann Hematol 1995;70:A53, 211.
Bucala R, Tracey KJ, Cerami A: Advanced glycation endproducts quench nitrite oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 1991;87:432–438.
Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern DM, Schmidt AM: Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996;97:238–243.
Bierhaus A, Ritz E, Nawroth PP: Expression of receptors for advanced glycation end-products in occlusive vascular and renal disease. Nephrol Dial Transplant 1996;11(suppl 5):87–90.
Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle P, Neumeier D: Activated transcription factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996;97:1715–1722.
Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M: Advanced glycation endproducts induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994;91:11704–11708.
Vlassara H, Fuh H, Donnelly T, Cybulsky M: Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1995;1:447–456.
Edelstein D, Brownlee M: Mechanistic studies of advanced glycosylation endproduct inhibition by aminoguanidine. Diabetes 1992;41:26–29.
Li Y-M, Steffes M, Donnelly T, Liu C, Fuh H, Basgen J, Bucala R, Vlassara H: Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci USA 1996;93:3902–3907.
Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, Cerami A, Bucala R: Hemoglobin-AGE: A circulating marker of advanced glycosylation. Science 1992;258:651–653.
Münch G, Thome J, Foley P, Schinzel R, Riederer P: Advanced glycation endproducts in ageing and Alzheimer’s disease. Brain Res Rev 1997;23:134–143.
Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P: An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996;382:275–278.
Packer L, Witt EH, Tritschler HJ: Alpha-lipoic acid as a biological antioxidant. Free Rad Biol Med 1995;19:227–250.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.